ProfileGDS4814 / ILMN_1669747
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 82% 83% 83% 81% 84% 83% 83% 83% 82% 81% 82% 83% 80% 82% 81% 81% 81% 80% 82% 83% 81% 83% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)173.44982
GSM780708Untreated after 4 days (C2_1)189.50883
GSM780709Untreated after 4 days (C3_1)189.91883
GSM780719Untreated after 4 days (C1_2)159.67281
GSM780720Untreated after 4 days (C2_2)204.56284
GSM780721Untreated after 4 days (C3_2)194.23383
GSM780710Trastuzumab treated after 4 days (T1_1)184.25983
GSM780711Trastuzumab treated after 4 days (T2_1)193.01383
GSM780712Trastuzumab treated after 4 days (T3_1)176.67182
GSM780722Trastuzumab treated after 4 days (T1_2)159.54681
GSM780723Trastuzumab treated after 4 days (T2_2)177.83182
GSM780724Trastuzumab treated after 4 days (T3_2)196.68683
GSM780713Pertuzumab treated after 4 days (P1_1)150.43880
GSM780714Pertuzumab treated after 4 days (P2_1)175.25482
GSM780715Pertuzumab treated after 4 days (P3_1)153.30281
GSM780725Pertuzumab treated after 4 days (P1_2)158.20381
GSM780726Pertuzumab treated after 4 days (P2_2)162.50981
GSM780727Pertuzumab treated after 4 days (P3_2)144.7180
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)175.79682
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)182.84183
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)155.02681
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)195.40183
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)173.74782